XML 94 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Business combinations and investments - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Aug. 02, 2021
Jun. 08, 2021
Mar. 30, 2021
Nov. 30, 2020
Oct. 05, 2020
Jul. 15, 2020
Mar. 27, 2020
Jan. 22, 2020
Aug. 23, 2019
Jan. 30, 2018
Jul. 03, 2021
Jun. 27, 2020
Jul. 03, 2021
Jul. 03, 2021
Jun. 27, 2020
Dec. 31, 2020
Dec. 31, 2019
Jun. 24, 2021
Jan. 31, 2020
Business Acquisition [Line Items]                                      
Expected future amortization, remainder of fiscal year     $ 2,238                                
Expected future amortization, year one     4,475                         $ 28,262      
Expected future amortization, year two     4,381                         23,910      
Expected future amortization, year three     4,350                         22,297      
Expected future amortization, year four     $ 4,350                         $ 22,297      
Acquisition costs                     $ 1,833   $ 5,029            
Revenue of acquiree since acquisition date                     11,870   3,529            
Acquisition integration costs and inventory related adjustments                     3,939   $ 7,135            
Variable interest entity, ownership percentage                         8.80%            
Impairment of variable interest entity assets                     5,674 $ 0   $ 5,674 $ 0        
Impairment of variable interest entity assets, attributable to noncontrolling interest   $ 5,176                                  
Impairment of variable interest entity   $ 1,369                                  
Equity method investments                     $ 17,737   $ 17,737 $ 17,737          
Equity method investment, ownership percentage                     10.03%   10.03% 10.03%          
Income (loss) from equity method investments                     $ 432   $ 901            
Period after receipt of statistical report for which the company may terminate agreement 30 days                                    
Payment due upon termination of agreement $ 30,000                                    
Escrow deposit 50,000                                    
Consideration transferred upon achievement of certain sales milestones 150,000                                    
Consideration payable upon closing $ 314,895                                    
Variable interest entity, ownership percentage                         8.80%            
Debt instrument interest rate percentage                     2.60%   2.60% 2.60%          
Equity method investment ownership percentage                     10.03%   10.03% 10.03%          
Equity method investment                     $ 17,737   $ 17,737 $ 17,737          
Net losses from equity method investment                     $ 432   $ 901            
Vaporox                                      
Business Acquisition [Line Items]                                      
Investment owned, balance, shares (in shares)                                   406,504  
Investment owned, ownership percentage                                   6.00%  
Investment owned, cost                                   $ 1,000  
Bioness, Inc                                      
Business Acquisition [Line Items]                                      
Percentage of business acquired     100.00%               100.00%   100.00% 100.00%          
Contingent consideration at fair value     $ 43,000                                
Escrow deposit     4,207                                
Consideration payable upon closing     91,933                                
Bioness, Inc | Maximum                                      
Business Acquisition [Line Items]                                      
Contingent consideration at fair value     65,000                                
Bioness, Inc | Convertible Debt                                      
Business Acquisition [Line Items]                                      
Repayments of convertible debt     1,500                                
Bioness, Inc | Obtaining FDA Approval Of Certain Products                                      
Business Acquisition [Line Items]                                      
Contingent consideration at fair value     15,000                                
Bioness, Inc | Meeting Net Sales Targets Over A Three-Year Period, Payment One                                      
Business Acquisition [Line Items]                                      
Contingent consideration at fair value     20,000                                
Bioness, Inc | Meeting Net Sales Targets Over A Three-Year Period, Payment Two                                      
Business Acquisition [Line Items]                                      
Contingent consideration at fair value     10,000                                
Bioness, Inc | For Obtaining CMS Coverage And Reimbursement For Certain Products                                      
Business Acquisition [Line Items]                                      
Contingent consideration at fair value     $ 20,000                                
CartiHeal                                      
Business Acquisition [Line Items]                                      
Percentage of business acquired                     100.00%   100.00% 100.00%          
Period after FDA approval for which company may exercise option to purchase remaining equity                         45 days            
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity                         45 days            
Period after FDA approval for which company may exercise option to purchase remaining equity                         45 days            
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity                         45 days            
CartiHeal | Series G Preferred Stock                                      
Business Acquisition [Line Items]                                      
Additional shares to be purchased upon completion of study (in shares)                     338,089   338,089 338,089          
Additional investment to be purchased upon completion of study                     $ 5,000   $ 5,000 $ 5,000          
Additional shares to be purchased upon completion of study (in shares)                     338,089   338,089 338,089          
Additional investment to be purchased upon completion of study                     $ 5,000   $ 5,000 $ 5,000          
Bio Ventus LLC                                      
Business Acquisition [Line Items]                                      
Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate, percentage                               16.50%      
Bio Ventus LLC | In Process Research and Development                                      
Business Acquisition [Line Items]                                      
Intangible assets fair value disclosure                               $ 1,445      
Bio Ventus LLC | Promissory Note | Harbor Common Stock                                      
Business Acquisition [Line Items]                                      
Debt conversion converted instrument warrants issued             428,572                        
Bio Ventus LLC | Harbor Medtech Inc                                      
Business Acquisition [Line Items]                                      
Percentage of noncontrolling interest                               91.20%      
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Promissory Note                                      
Business Acquisition [Line Items]                                      
Debt conversion converted instrument amount             $ 500                        
Debt instrument convertible conversion exercisable price             $ 1.167                        
Maturity date             Mar. 27, 2025                 Aug. 31, 2021 Aug. 31, 2020    
Debt instrument face amount       $ 320                              
Refinanced with additional borrowings amount                               $ 1,811      
Debt instrument interest rate percentage                               8.00%      
Debt instrument frequency of periodic payment                               monthly      
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Promissory Note | Other Current Liabilities                                      
Business Acquisition [Line Items]                                      
Debt instrument face amount                                 $ 1,845    
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Series C Preferred Stock                                      
Business Acquisition [Line Items]                                      
Stock issued during period shares new issues         285,714                            
Stock issued during period value new issues         $ 1,000                            
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Series C Preferred Stock | Promissory Note                                      
Business Acquisition [Line Items]                                      
Debt conversion converted instrument shares issued       92,500     142,858                        
Debt instrument convertible conversion price       $ 3.50                              
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Medtech Inc | Series C Preferred Stock                                      
Business Acquisition [Line Items]                                      
Variable interest entity, ownership percentage                 3.10%                    
Variable interest entity shares purchased                 285,714                    
Variable interest entity, ownership percentage                 3.10%                    
Variable interest entity cost                 $ 1,000                    
Bio Ventus LLC | CartiHeal Ltd                                      
Business Acquisition [Line Items]                                      
Equity method investments           $ 16,579                   $ 18,689      
Equity method investment, ownership percentage                   2.80%                  
Income (loss) from equity method investments                               $ (467)      
Period after FDA approval for which company may exercise option to purchase remaining equity                               45 days      
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity                               45 days      
Equity method investment ownership percentage                   2.80%                  
Equity method investment aggregate cost                   $ 2,500                  
Equity method investment capitalized transaction costs           1,427                         $ 152
Equity method investment           $ 16,579                   $ 18,689      
Net losses from equity method investment                               $ (467)      
Period after FDA approval for which company may exercise option to purchase remaining equity                               45 days      
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity                               45 days      
Bio Ventus LLC | CartiHeal Ltd | Option and Equity Purchase Agreement                                      
Business Acquisition [Line Items]                                      
Increase in equity ownership percentage           10.03%                          
Bio Ventus LLC | CartiHeal Ltd | Simple Agreement For Future Equity                                      
Business Acquisition [Line Items]                                      
Additional investment,cash paid               $ 152                      
Bio Ventus LLC | CartiHeal Ltd | Series G Preferred Stock                                      
Business Acquisition [Line Items]                                      
Additional shares to be purchased upon completion of study (in shares)                               338,089      
Additional investment to be purchased upon completion of study                               $ 5,000      
Additional shares to be purchased upon completion of study (in shares)                               338,089      
Additional investment to be purchased upon completion of study                               $ 5,000      
Bio Ventus LLC | CartiHeal Ltd | Series G Preferred Stock | Option and Equity Purchase Agreement                                      
Business Acquisition [Line Items]                                      
Additional shares purchased           1,014,267                          
Additional shares purchased Value           $ 15,000                          
Bio Ventus LLC | CartiHeal Ltd | Series F Convertible Preferred Stock                                      
Business Acquisition [Line Items]                                      
Number of shares issued                   337,397                  
Bio Ventus LLC | CartiHeal Ltd | Series G1 Preferred Stock                                      
Business Acquisition [Line Items]                                      
Number of shares issued           12,825